Scarica l'app Stockscreener
6.80
6.25%
0.40
Dopo l'orario di chiusura:
6.91
0.11
+1.62%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Precedente Chiudi:
$6.40
Aprire:
$5.62
Volume 24 ore:
35.31M
Relative Volume:
5.40
Capitalizzazione di mercato:
$82.18M
Reddito:
$1.38M
Utile/perdita netta:
$-179.05M
Rapporto P/E:
-1.1075
EPS:
-6.14
Flusso di cassa netto:
$-155.03M
1 W Prestazione:
+128.96%
1M Prestazione:
+245.18%
6M Prestazione:
+141.99%
1 anno Prestazione:
+934.22%
Intervallo 1D:
$4.80
$8.08
Intervallo di 1 settimana:
$2.98
$8.08
Portata 52W:
$0.16
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Nome
Bioxcel Therapeutics Inc
Settore
Industria
Telefono
203-643-8060
Indirizzo
555 LONG WHARF DRIVE, NEW HAVEN, CT
Confronta BTAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
6.80 | 38.76M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-21 | Downgrade | UBS | Buy → Neutral |
| 2023-08-15 | Downgrade | Mizuho | Buy → Neutral |
| 2023-07-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-03-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-12-01 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-04-06 | Reiterato | BofA Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-09 | Iniziato | Berenberg | Buy |
| 2021-02-01 | Iniziato | UBS | Buy |
| 2020-10-30 | Iniziato | Goldman | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-04 | Iniziato | Guggenheim | Buy |
| 2020-04-01 | Iniziato | BofA/Merrill | Buy |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
Mostra tutto
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
Bioxcel Therapeutics 2025 Q2 Earnings Widened Net Loss Amid Revenue Drop - AInvest
BioXcel Therapeutics Reports Q2 2025 Financial Results - TipRanks
BIOXCEL THERAPEUTICS Earnings Results: $BTAI Reports Quarterly Earnings - Quiver Quantitative
BioXcel Therapeutics (BTAI): Assessing the Impact of SERENITY Trial Outcomes on At-Home Agitation Market Potential - AInvest
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
BioXcel at Canaccord Genuity: Strategic Insights on Phase 3 Trials By Investing.com - Investing.com Canada
BioXcel Therapeutics (BTAI) Q2 Financial Report: Wider Loss, Revenue Decrease, and Upcoming Business Updates - AInvest
BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On? - Benzinga
BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments - StocksToTrade
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
Bioxcel Therapeutics Plunges 12.03% on Q2 Loss, Revenue Drop - AInvest
BioXcel Therapeutics Q2 Earnings Miss Estimates, Revenue Down 89.1% Y/Y - AInvest
BioXcel Therapeutics Inc Reports Q2 2025 Earnings: EPS of -$1.56, Revenue Misses Estimates at $120K - GuruFocus
BioXcel Therapeutics Reports Q2 2025 Financials, Topline Data Expected in August. - AInvest
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - TradingView
BioXcel Therapeutics' Q2 2025 Earnings Disappointment: A Test of Biotech Resilience - AInvest
BioXcel's Breakthrough Agitation Drug Targets 23M Episodes Annually: Phase 3 Data Due This Month - Stock Titan
Bioxcel Therapeutics Surges 58.42% on $230M Volume Ranks 452nd in Market Activity as BXCL501 Trial Progress Fuels Investor Optimism - AInvest
BioXcel Therapeutics to Participate in Canaccord Genuity Growth Conference - AInvest
BioXcel Therapeutics Raises $30.4M, Meets Financing Covenant - TipRanks
Bioxcel Therapeutics (BTAI.O) Surges Over 21%: A Deep Dive Into the Drivers Behind the Unusual Move - AInvest
BioXcel’s BXCL501 Study: A Potential Game-Changer for Psychomotor Agitation Treatment - TipRanks
BioXcel Highlights BXCL501’s Market Potential for Agitation - TipRanks
BioXcel Therapeutics CEO to speak at Canaccord Genuity Growth Conference. - AInvest
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
BioXcel CEO Reveals Next-Gen AI Neuroscience Innovations at Major Growth ConferenceStrategic Updates Coming - Stock Titan
Bioxcel Therapeutics (BTAI.O) Surges 12.6% Without Fundamental Catalyst: A Technical and Order-Flow Deep Dive - AInvest
Bioxcel Therapeutics (BTAI) Surges 28% on Intraday Rally: What’s Fueling the Momentum? - AInvest
BTAI Surges 27% on Unprecedented Momentum: What’s Fueling the Biotech Breakout? - AInvest
Top Penny Stocks to Watch: Ainos, SG Blocks, and BioXcel Therapeutics - AInvest
BioXcel Therapeutics Sees Stock Surge Amid Positive Phase 3 Results in At-Home Trial - timothysykes.com
Best Penny Stocks To ConsiderAugust 5th - MarketBeat
BioXcel Therapeutics Stock (BTAI) Opinions on Phase 3 SERENITY Trial Completion - Quiver Quantitative
BioXcel Therapeutics Anticipates Major Breakthrough with Completion of SERENITY At-Home Trial - StocksToTrade
Bioxcel Therapeutics (BTAI.O) Surges 17.17%—What’s Driving the Intraday Move? - AInvest
Bioxcel Therapeutics shares rise 4.38% premarket after publication in Frontiers in Pharmacology. - AInvest
Bioxcel Therapeutics Soars 11.11% on Positive Drug Study - AInvest
BioXcel Study Highlights Dexmedetomidine’s Potential Benefits - TipRanks
Bioxcel Therapeutics shares rise 11.78% premarket after positive study results for BXCL501 in chronic psychiatric disorders. - AInvest
BioXcel study shows dexmedetomidine reduces stress behaviors By Investing.com - Investing.com Nigeria
BioXcel study shows dexmedetomidine reduces stress behaviors - Investing.com India
BTAI files 424B5 to sell up to $3.5M in stock via ATM program - Stock Titan
BioXcel Therapeutics Announces Publication in Frontiers in - GlobeNewswire
Breakthrough Study: BioXcel's BXCL501 Could Transform Treatment of Chronic Psychiatric Disorders - Stock Titan
Mizuho Securities Maintains Hold Rating for Bioxcel Therapeutics with $2.00 Price Target - AInvest
Bioxcel Therapeutics Soars 27% Intraday: What's Fueling This Biotech Surge? - AInvest
BioXcel’s Clinical Breakthrough Marks Market Anticipation - timothysykes.com
Bioxcel Therapeutics (BTAI.O) Surges 13.39%: What’s Behind the Unusual Intraday Move? - AInvest
3 Penny Stocks to Watch: Tenon Medical, BioXcel Therapeutics, I-Mab - AInvest
Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):